Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 16 |
| Active Pipeline (Recruiting Now) | 12 (5) |
| Completed vs Stopped Early | 3 / 1 (6.3%) |
| Median Closed Actual Enrollment | 44 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Hospital Universitario Fundación Jiménez Díaz | Madrid | 16 |
| Hospital Universitari Vall d'Hebron | Barcelona | 13 |
| Hospital de La Santa Creu I Sant Pau | Barcelona | 11 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07242547 | Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients | Phase II | RECRUITING |
| NCT07153445 | Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC) | Phase II | RECRUITING |
| NCT06431633 | Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were | Phase III | RECRUITING |
| NCT06917573 | PALACE: Cemiplimab Trial According to ctDNA Levels | Phase II | RECRUITING |
| NCT05398094 | Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Fundación GECP Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.